RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
  AIIMS
  Madhya Pradesh
  Medical Tourism
  Orissa Healthcare
  Maharashtra
  Bihar
  Uttar Pradesh Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
India Healthcare Channel

subscribe to India Healthcare newsletter
Healthcare : India Healthcare

   EMAIL   |   PRINT
Ranbaxy launches new dental drug in India, Nepal

Mar 18, 2008 - 5:42:14 PM
Sanjeev I. Dani, senior vice-president and regional director Asia and CIS, Ranbaxy, said: 'Periodontitis, gingivitis and halitosis are common dental problems which if ignored, can lead to more serious complications.

 
[RxPG] Mumbai, March 18 - Pharma major Ranbaxy Laboratories Tuesday launched the first-of-its-kind natural and probiotic drug for dental diseases in India and Nepal.


In a filing with the Bombay Stock Exchange - Tuesday, the company said the exclusive in-licensing agreement for marketing the drug, Inersan, has been signed with CD Pharma, a subsidiary of the US-based VSL Pharmaceuticals.

The drug is used for the treatment of dental problems like periodontitis, gingivitis and halitosis.

Ranbaxy claimed that at present there was no drug available for the treatment of such dental problems and Inersan will be the first-of-its-kind to be introduced in India and Nepal.

According to the release, early-stage periodontitis - is painful causing swelling and bleeding in gums. The disease usually leads to serious infection and loss of tooth. Dentists normally recommend surgical options such as flap surgery, soft tissue grafting or bone grafting and guided tissue regeneration.

Moreover, quoting medical studies, Ranbaxy said women with advanced gum diseases become prone to pre-mature delivery of baby and oral microbes affect the fetus. Even cardiac patients have been asked to be careful of periodontitis as bacteria from mouth can cause clotting problems in the cardiovascular system.

Sanjeev I. Dani, senior vice-president and regional director Asia and CIS, Ranbaxy, said: 'Periodontitis, gingivitis and halitosis are common dental problems which if ignored, can lead to more serious complications.

'Dental practitioners in India currently do not have any specialised prescription product for these conditions and Inersan tablets address this need for the segment,' he added.





Advertise in this space for $10 per month. Contact us today.


Related India Healthcare News


Subscribe to India Healthcare Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)